BioStock: New findings support the use of RhoVac’s cancer vaccine in several forms of cancer

Whilst waiting on the readout of the BRaVac phase IIb study, RhoVac continues to build its data package around the cancer vaccine candidate onilcamotide. The company recently announced new preclinical findings suggesting that the candidate may have a role to play in several different forms of cancer. BioStock contacted RhoVac’s CEO Anders Månsson to find out what this means for the project as a whole.

Read the full article at biostock.se:

https://www.biostock.se/en/2022/05/new-findings-support-the-use-of-rhovacs-cancer-vaccine-in-several-forms-of-cancer/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se